Witz CA, Daftary GS, Doody KJ, et al. - Researchers conducted a randomized, open-label, assessor-blinded, parallel-group, noninferiority trial investigating the efficacy and safety of highly purified human menotropin (HP-hMG) and recombinant follicle-stimulating hormone (rFSH) for controlled ovarian stimulation in a population of patients predicted to be high responders. Among a total of 620 women with serum antimüllerian hormone (AMH) ≥ 5 ng/mL, controlled ovarian stimulation was performed with either HP-hMG or rFSH in a GnRH antagonist assisted reproductive technology (ART) cycle. They performed fresh transfer of a single blastocyst until achievement of excessive ovarian response, in which all embryos were cryopreserved. Subsequent frozen blastocyst transfer could be performed in the individuals within 6 months of randomization. Outcomes revealed comparable efficacy of HP-hMG to rFSH in high responders with fewer adverse events, including pregnancy loss, indicating its optimized risk/benefit profile in this population.